A life-saving breakthrough can still be inadequate. The obligation is to return to the drawing board for something better.
A life-saving breakthrough can still be inadequate. The obligation is to return to the drawing board for something better.
![John Crowley - Biotech's Chief Evangelist - [Art of Investing, EP.15]](https://megaphone.imgix.net/podcasts/c90bd084-e311-11ee-be41-d73b90879448/image/50d7c1b22c46d0e8199c451593610ee5.png?ixlib=rails-4.3.1&max-w=3000&max-h=3000&fit=crop&auto=format,compress)
More from this episode
See all →The initial Pompe treatment made two adult patients weaker, prompting Amicus to stop the trial and…
A German infant failing approved Pompe therapy improved on Amicus’s experimental treatment,…
The failed Pompe drug weakened patients because its half-life in human muscle differed from its…
The Pompe enzyme treatment normalized the children’s enlarged hearts within six infusions or 12…
In the 1990s, science and biopharma transformed HIV/AIDS from a death sentence into a manageable…
A doctor predicted a Pompe disease cure within about a year. Nearly 25 years later, that goal…
About 90% of drugs entering clinical trials never become commercial products, while about 90% of…
An angel round raised $1 million from 37 individual investors after the minimum investment fell…
Don't lose this one
A free account saves cards like this to your Collection, and Korva resurfaces them so you actually remember.